MYD88 mutated and wild-type Waldenström’s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4
- 28 March 2018
- journal article
- letter
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 103 (9), e408-e411
- https://doi.org/10.3324/haematol.2018.190181
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andoverall survivalBritish Journal of Haematology, 2018
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemiaBlood, 2016
- Clonal architecture of CXCR4 WHIM‐like mutations in Waldenström MacroglobulinaemiaBritish Journal of Haematology, 2015
- The cellular origin and malignant transformation of Waldenström macroglobulinemiaBlood, 2015
- MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significanceBlood, 2013
- Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemiaAmerican Journal of Hematology, 2013
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding proteinNature Immunology, 2001
- Btf, a Novel Death-Promoting Transcriptional Repressor That Interacts with Bcl-2-Related ProteinsMolecular and Cellular Biology, 1999